Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Oncología (Barcelona)
versão impressa ISSN 0378-4835
Resumo
VALVERDE ALMOHALLA, S.; DIAZ VEGA, B.; TOMAS SAN PEDRO, J. M. e ENCINAS MARTIN, J. L.. Brachytherapy with extrascleral iridium-192 wires in posterior uveal melanoma: Long-term results. Oncología (Barc.) [online]. 2005, vol.28, n.9, pp.11-21. ISSN 0378-4835.
PURPOSE: To assess the long-term efficay and safeness of iridium-192 wires brachytherapy in posterior uveal melanoma. MATERIAL AND METHODS: Non-controlled retrospective series of 241 patients, treated from January 1983 to July 2005 in a national referral hospital. RESULTS: The mean follow-up was of 5.4 years, with 17% of the patients lost for follow-up. The 5-year and 10-year probability of disease-free survival was 77% (95% IC: 56; 73) and 64% (95% IC: 56; 73); and of eye conservation, 74% (95% IC: 68; 80) and 63% (95% IC: 55; 71). The 1-year, 5-year and 10-year probability of visual acuity conservation of at least 20/400 was 64% (95% IC: 57; 71), 28% (95% IC: 21; 35) and 15% (95% IC: 8; 23), respectively. The 5-year probability of enucleation due to complications was 11% (95% IC: 6; 16) for choroidal melanomas, and 58% (95% IC: 27; 89) for ciliary body melanomas (p < 0.001). CONCLUSION: Iridium-192 wire brachytherapy achieves a disease control similar to that obtained with iodine-125 plaques, but the rate of complications requiring a secondary enucleation seems to be greater with the iridium-192 procedure, especially in ciliary body melanomas.
Palavras-chave : Uveal neoplasms; Melanoma; Brachytherapy; Iridium radioisotope; Survival rate; Disease-free survival.